Neurospine.  2022 Mar;19(1):13-29. 10.14245/ns.2143210.605.

Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas

• Grady C
• Melnick K
• Porche K
• Dastmalchi F
• Hoh DJ
• Rahman M
• Ghiaseddin A

• KMID: 2528371
• DOI: http://doi.org/10.14245/ns.2143210.605

Abstract

Spinal cord gliomas are rare entities that often have limited surgical options. Immunotherapy has shown promise in intracranial gliomas with some research suggesting benefit for spinal cord gliomas. A focused review of immunotherapies that have been investigated in spinal cord gliomas was performed. The primary methods of immunotherapy investigated in spinal cord gliomas include immune checkpoint inhibitors, adoptive T-cell therapies, and vaccine strategies. There are innumerable challenges that must be overcome to effectively apply immunotherapeutic strategies to the spinal cord gliomas including low incidence, few antigenic targets, the blood spinal cord barrier, the immunosuppressive tumor microenvironment and neurotoxic treatment effects. Nonetheless, research has suggested ways to overcome these challenges and treatments have been effective in case reports for metastatic non-small cell lung cancer, melanoma, midline glioma and glioblastoma. Current therapies for spinal cord gliomas are markedly limited. Further research is needed to determine if the success of immunotherapy for intracranial gliomas can be effectively applied to these unique tumors.

Keyword

Immunotherapy; Tumor; Glioma; Ependymoma; Intramedullary